PerpEquitiesEquity · Healthcare
Biogen Inc. (BIIB) perpetual futures
BIIB perpetual futures on 3 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade BIIBUSDT.
Biogen Inc. is a biotechnology company developing and commercializing therapies for neurological and neurodegenerative diseases, including multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease.
Price chart
Use the left and right arrow keys to inspect points on the chart.
Trading data
Perpetual market activity
3/3 live markets
Trading data
Perpetual market activity
Spot performance
Venue matrix
3 markets
Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.
BingX
Bybit
Gate.ioTradability
Execution quality
Entry cost and depth per venue at $1k–$100k
Tradability
Execution quality
Entry cost and depth per venue at $1k–$100kNo sufficient depth · 0 of 3 venues absorb $10k
Too thin: BingX, Bybit
No fresh book data: Gate.io
Taker execution estimate incl. approx. fees - maker fills are not guaranteed.
Best venues for this underlying
Best liquidity
BIIBTightest spread
BIIBHighest volume
BIIBFunding history
Stored venue snapshots by market
Funding history
Stored venue snapshots by marketCompany data
Company fundamentals
Updated 1h ago
Company data
Company fundamentals
More metrics
Fundamental detail
Annual + quarterlyRefreshed 1h ago
Charts: revenue, profit, cash flow & valuation
Next catalyst
Catalysts
Next catalyst
Catalysts
No unusual perp activity right now.
Research data
Analysts, filings and peer context
Research data
Analysts, filings and peer context
Estimates
6Company events
6Peer comparison
Similar listed perpsRevenue mix
PendingAnalysts
PendingOwnership
BIIB-PERPFilings
PendingTranscripts
PendingLatest updates
No recent updates available.FMP company data
Company intelligence
Updated: Sep 19, 2026, 01:42 PM UTC
FMP company data
Company intelligence
Company profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Chief executive
- Christopher A. Viehbacher
- Employees
- 7,500
- IPO date
- Sep 17, 1991
- Country
- US
- Exchange
- NASDAQ Global Select
Rating factors
- Return on equityi
- 3
- Return on assetsi
- 4
- Debt to equityi
- 2
- Price to earningsi
- 1
- Price to booki
- 3
Company press releases
Congressional disclosures
Senate
House
Market cap history
Largest fund holders
| Fund | Weight | Shares held |
|---|---|---|
| VPMAX | 1.88% | 8.4M |
| VTI | 0.04% | 4.7M |
| FCNKX | 0.59% | 4.7M |
| VOO | 0.05% | 3.9M |
| VCPA.S | 0.07% | 3.6M |
| VO | 0.3% | 3.2M |
| VHCAX | 1.72% | 2.6M |
| VGHAX | 1.4% | 2.5M |
| IVV | 0.05% | 1.9M |
| FXAIX | 0.05% | 1.8M |
| 1557.T | 0.05% | 1.8M |
| SPY | 0.05% | 1.8M |
Analyst track record
How the analysts covering BIIB have done: ratings, price-target accuracy and the measured reaction after their calls.
| 12 months | 3 years | |
|---|---|---|
| Ratings | 236 | 677 |
| Analysts | 35 | 42 |
| Buy / hold / sell | 120 / 111 / 5 | 393 / 279 / 5 |
| Upgrades / downgrades / initiations | 7 / 2 / 4 | 8 / 12 / 10 |
| Price targets hit / missed | 126 / 74 (63%) | 265 / 316 (46%) |
| Avg. return after a rating (TipRanks) | +8.1% | +2.3% |
| Best / worst call | +85.6% / -27.0% | +90.5% / -45.2% |
After buy calls on this stock: median 21-day move +0.6% vs S&P 500 -1.8% (n = 395)
Most accurate on this stock
Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.
- Salveen RichterGoldman Sachs50% hit rate on this stock · 12 targets measuredBuytarget $250Jul 13, 2026
- Andrew FeinH.C. Wainwright42% hit rate on this stock · 12 targets measuredBuytarget $251Jul 30, 2026
- Phil NadeauTD Cowen41% hit rate on this stock · 17 targets measuredBuytarget $225Jul 30, 2026
Latest ratings
| Date | Analyst | Call | Target | |
|---|---|---|---|---|
| Sep 18, 2026 | Mohit BansalWells Fargo | BuyMaintained | $250 | article ↗ |
| Sep 18, 2026 | Mohit BansalWells Fargo | BuyMaintained | $250 | |
| Sep 10, 2026 | Morten HerholdtHSBC | SellMaintained | $175 | article ↗ |
| Sep 9, 2026 | Evan SeigermanBMO Capital | HoldMaintained | – | article ↗ |
| Sep 3, 2026 | David AmsellemPiper Sandler | BuyReiterated | $245 | article ↗ |
Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.
TipRanks data via FMP · computed Sep 18, 2026 · 236 ratings
Frequently asked questions
Where can I trade BIIB perpetual futures?
Biogen Inc. (BIIB) perpetual futures trade on 3 crypto venues, including BingX, Bybit, Gate.io. PerpEquities compares them by live price, funding rate, open interest and liquidity.
Can I trade BIIB around the clock?
Yes. Unlike the underlying stock, BIIB perpetuals trade 24/7 — including weekends and outside regular market hours.
What is the funding rate on BIIB perpetuals?
Right now the BIIB perp funding rate is 0.0% annualized (venue median), ranging from -5.5% to 0.0% across 3 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.
How does the BIIB perp price compare to the Biogen Inc. stock?
The venue-median BIIB perp mark is $216.9 versus a reference stock price of $217.1, a basis of -0.1%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.
What is a BIIB perpetual future?
A BIIB perpetual is a derivative that tracks the price of Biogen Inc. with no expiry date. It lets you take long or short exposure to Biogen Inc. on crypto venues, around the clock.
What is BIIBUSDT perpetual?
BIIBUSDT is the symbol most crypto exchanges use for the Biogen Inc. perpetual settled in USDT (Tether). It tracks the BIIB share price through an index, trades 24/7 with leverage and never expires.
Embed this asset
<a href="https://perpequities.com/stocks/biib-perp"><img src="https://perpequities.com/badge/biib-perp.svg" width="240" height="64" alt="BIIB perpetuals · perpequities.com" loading="lazy"></a>